Multiple sclerosisRoches meets endpoints in relapsing multiple sclerosisLatest NewsRoche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis. Read more 17 May 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2023-05-17_um_09.31.59.png 912 1498 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-05-17 07:51:052024-07-12 11:22:38Roches meets endpoints in relapsing multiple sclerosis